Ardelyx, Inc. (ARDX) Earnings
Ardelyx, Inc. is expected to report next earnings on October 29, 2026 (in NaN days), with a consensus EPS estimate of $-0.03. ARDX has beaten EPS estimates in 5 of its last 12 reported quarters (average surprise -9.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.07 | $-0.07 | -7.0% | $121M | -0.1% |
| Apr 30, 2026 | $-0.13 | $-0.15 | -15.4% | $94M | +1.8% |
| Feb 19, 2026 | $0.02 | $-0.00 | -108.4% | $125M | +16.8% |
| Oct 30, 2025 | $-0.06 | $-0.00 | +93.3% | $110M | -7.3% |
| May 1, 2025 | $-0.10 | $-0.17 | -70.0% | $74M | -10.0% |
| Feb 20, 2025 | $0.02 | $0.02 | +0.0% | $116M | +55.8% |
| Oct 31, 2024 | $-0.05 | $-0.00 | +93.1% | $98M | -9.5% |
| Aug 1, 2024 | $-0.10 | $-0.07 | +30.0% | $73M | +33.1% |
| May 2, 2024 | $-0.13 | $-0.11 | +15.4% | $46M | +26.4% |
| Feb 22, 2024 | $-0.09 | $-0.12 | -33.3% | $34M | +0.4% |
| Aug 2, 2023 | $-0.12 | $-0.08 | +33.3% | $22M | +35.3% |
| May 3, 2023 | $-0.11 | $-0.13 | -18.2% | $11M | +7.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Commercial Performance and Core Business Position - The company delivered record-high quarterly revenue with robust year-over-year growth for both commercial products, though Ibsrella performance fell short of internal expectations due to unanticipated payer access hurdles. - Long-term confidence in Ibsrella's path to $1 billion in revenue remains unchanged, with Q2 2026 seeing record demand, total refills, prescriptions per prescriber, and market share since launch, highlighting strong underlying patient need. - Xposa delivered strong Q2 2026 momentum, with 33% year-over-year growth in total dispenses and 25% growth in paid prescriptions, reaching its highest total prescribers and prescriptions per prescriber since Q1 2025. ### Ibsrella Access Improvement Initiatives - Doubled the size of the dedicated field reimbursement management (FRM) team in H1 2026, with all new staff deployed in the field as of July 1, to help providers navigate burdensome prior authorization and step edit requirements. - Expanded the sales organization to 144 representatives to increase engagement frequency with high-priority prescribing healthcare providers, and is adding resources to drive more prescriptions through the Ibsrella Pharmacy Network (IPN), which delivers higher fulfillment rates, faster fills, and 1 additional annual refill per patient on average. - Launched new direct-to-consumer awareness initiatives in H2 2026, complementing existing omnichannel, digital, and LPGA partnership efforts, to drive patient-provider conversations that convert to new prescriptions. ### Pipeline and Operational Strategy - The company continues to advance Tenapenor (tenapanor) in Phase III development for CIC and its next-generation NHG3 inhibitor program, while actively pursuing business development opportunities to expand the pipeline. - A robust patent estate has been built for Ibsrella, anchored by the Orange Book-listed 299 formulation patent that provides exclusivity through 2042, with additional IP being added to further strengthen intellectual property protections. - Following the DC Circuit Court of Appeals' affirmation of the dismissal of the company's lawsuit against CMS, Ardelyx will not pursue further litigation, and remains committed to maintaining patient access to Xposa amid the resulting changed market dynamics. - The company maintains a strong, liquid balance sheet supported by revenue growth and disciplined capital allocation, and remains on track to achieve sustained profitability in 2027.
Guidance
- **2026 Ibsrella revenue guidance**: Lowered to a range of $350 - $370 million, which still represents more than 30% year-over-year growth at the midpoint. The guidance assumes ~60% of full-year revenue will be generated in H2 2026, consistent with historical sequential growth patterns. - **2026 Xposa revenue guidance**: Reaffirmed at $110 - $120 million. - **2026 OPEX guidance**: Revised downward to below $500 million, reflecting proactive spending discipline to offset lower Ibsrella revenue projections. - **Long-term revenue targets**: The company remains committed to Ibsrella reaching $1 billion in total revenue, but is re-evaluating the timing of this achievement following the 2026 downward revision. The $750 million long-term revenue guidance for Xposa has been pulled to account for ongoing market uncertainty resulting from regulatory and competitive transitions. - **Profitability guidance**: The company reaffirmed its expectation to achieve net income profitability in 2027, with net losses continuing to narrow on the path to positive cash flow.
Segment performance
Total product revenue for Q2 2026 was $118 million, representing 31% year-over-year growth, the highest quarterly revenue in company history. Ibsrella, the company's primary growth engine, generated revenue of $86.2 million, a 33% year-over-year increase, and accounted for 73% of total Q2 2026 revenue. Expedia (Xposa) generated revenue of $31.9 million, a 27% year-over-year increase, and accounted for 27% of total Q2 2026 revenue. R&D expenses for the quarter were $26.1 million, up from $15.7 million in Q2 2025, driven by Tenapenem Phase III trial development and patient enrollment costs. SG&A expenses were $101.4 million, up from $84 million in Q2 2025, reflecting investments to address Ibsrella access barriers. Net loss for the quarter was $16.7 million, narrowed from $19.1 million in Q2 2025. The company ended Q2 2026 with $281.8 million in cash, cash equivalents, and short-term investments.
Risks & headwinds
- Unanticipated stringent payer access hurdles (increased step edits and more rigorous prior authorization requirements) for Ibsrella have slowed new patient starts and created near-term revenue headwinds, and further access restrictions could emerge as the product grows. - The D.C. Circuit Court of Appeals' ruling upholding the bundling of oral-only phosphate-lowering therapies under CMS creates ongoing market uncertainty for Xposa, and changes to dialysis payment quality metrics and post-bundling market dynamics could negatively impact Xposa growth. - Ibsrella's strong growth makes it a likely target for generic competition, and while the company has a robust intellectual property estate, generic challenges could impact long-term revenue projections. - Pipeline development carries inherent clinical and regulatory risk, and the Phase III trial for Tenapenor may not meet its endpoints in the expected timeframe or deliver positive results.
Analyst Q&A
Q: What underlying demand metrics support confidence in the revised Ibsrella guidance, and what factors are baked into the new revenue range? /
A: The company continues to see strong refills and total prescriptions, with Q2 2026 delivering the highest demand quarter for Ibsrella to date. Prescriptions routed through the IPN consistently deliver higher fulfillment and retention, which the company is leaning into for H2 2026. All observed H1 2026 access friction and projected improvement from new initiatives have been fully factored into the revised guidance.
Q: Can you detail the specific Ibsrella payer hurdles, and how has the access environment changed recently? /
A: The primary new changes are an increase in step edit requirements and more stringent prior authorization standards that have slowed, but not completely blocked, new patient starts. The speed and scope of these new requirements were faster and more extensive than the company anticipated, coming in response to Ibsrella's rapid growth over the past two years. The company has now deployed additional FRMs to help patients and providers navigate these new barriers.
Q: Why did Ardelyx withdraw the $750 million long-term Xposa revenue guidance rather than revising it lower? /
A: The company is nearing the end of the current Medicaid Drug Rebate Program (MDRP) period, and new CMS phosphorus-focused quality measures (QIP) are being implemented for dialysis providers. The company needs time to assess how dialysis organizations will respond to these new rules and how upcoming competitor product approvals will impact market dynamics. Management only provides guidance when it has a high degree of confidence in projections, so stepping back was the most prudent approach.
Q: How does Ardelyx view its current business development environment and pipeline expansion strategy? /
A: The company evaluates a substantial number of potential acquisition and licensing opportunities regularly, and continues to actively pursue transactions that fit its strategic goals. The company's growing cash flow and long intellectual property exclusivity for its existing products give it significant flexibility to build out its pipeline, with Tenapenor alone providing substantial long-term revenue runway through 2042.